Search results for " vaccine"

showing 10 items of 680 documents

COVID-19 Vaccination in Pediatric Population: A Necessity or Obstruction to the Protection of the Right to Health? Biojuridical Perspective.

2022

One of the most recently debated topics worldwide is the mass vaccination of children against coronavirus disease 2019 (COVID-19). Next, the risk/benefit ratio of COVID-19 vaccination and infection in children are compared. Nonetheless, the real question in this debate is as follows: Does the vaccine represent a necessary tool or is it an obstacle in protecting the right to health? From a public health point of view, the Supreme Court of Nova Scotia, in Canada, recommends COVID-19 vaccination in the pediatric population. Based on Article 25 of the Draft Articles on State responsibility, vaccination can be considered a social act necessary for protecting the individual's right to health. The…

COVID-19 VaccinesSettore MED/43 - Medicina LegaleRight to Healthcovid 19 vaccination pediatric populationVaccinationPublic Health Environmental and Occupational HealthCOVID-19HumansChildSystemic Inflammatory Response SyndromeFrontiers in public health
researchProduct

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pande…

2020

Background Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods A literature search was performed for the screening of natural and derived bio-active compounds which showed po…

COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug Evaluation PreclinicalPharmaceutical ScienceAntiviral AgentsArticle03 medical and health scienceschemistry.chemical_compoundClinical trials0302 clinical medicineTocilizumabChloroquineDrug DiscoveryPandemicmedicineHumansAntiviralPandemics030304 developmental biologyPharmacologyBiological ProductsClinical Trials as TopicNatural products0303 health sciencesProtectionMolecular StructureTraditional medicineSARS-CoV-2business.industryCOVID-19LycorineFingolimodCOVID-19 Drug TreatmentClinical trialConessineComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicinePatentPlant Preparationsbusinessmedicine.drugPhytomedicine
researchProduct

Who should get COVID-19 vaccine first? A survey to evaluate hospital workers’ opinion

2021

Prospective planning of COVID-19 vaccines allocation will be essential to maximize public health and societal benefits while preserving equity. Decisions about how to allocate limited supplies of vaccines need to be clear about the criteria used in setting priorities, with a specific commitment to transparency and communication. The aim of our study was to think through these competing demands, focusing on the opinion of healthcare workers (HCWs). The primary endpoint of the study was to assess the opinion of all the HCWs in a University based Italian Hospital about the fairest priority order to COVID 19 vaccines and to understand on which criteria the prioritization preferences of HCWs are…

COVID-19 vaccine; prioritization; allocation; distribution; public health ethics; healthcare workersmedicine.medical_specialty030231 tropical medicineImmunologyPopulationeducationPsychological interventionlcsh:MedicineAllocation COVID-19 vaccine Distribution Healthcare workers Prioritization Public health ethicsArticleHerd immunity03 medical and health sciences0302 clinical medicineallocationDrug DiscoveryHealth caremedicinedistributionPharmacology (medical)030212 general & internal medicineeducationMultiple choicePharmacologyeducation.field_of_studypublic health ethicsbusiness.industryhealthcare workersPublic healthlcsh:RLaw enforcementprioritizationVaccinationInfectious DiseasesFamily medicinebusinessCOVID-19 vaccine
researchProduct

Reversible radiculomyelitis after ChAdOx1 nCoV-19 vaccination

2022

Adverse events occurring after SARS-CoV-2 vaccination have been reported and are the subject of ongoing research. We present the case of a young woman with fully reversible radiculomyelitis, which happened after the first dose of the ChAdOx1 nCOVID-19 vaccine. A previously healthy woman in her 20s presented with a subacute onset of legs’ weakness and sensory disturbances, urinary dysfunction and cramping pain after receiving the first dose of the ChAdOx1 nCoV-19 vaccine. A diagnostic workup led to the diagnosis of inflammatory radiculomyelitis. Her clinical status improved, with complete recovery after a few months. The case described a reversible radiculomyelitis associated with the ChAdOx…

COVID-19 myeloradiculoneuritis case reportCOVID-19 VaccinesSARS-CoV-2ChAdOx1 nCoV-19VaccinationCOVID-19HumansFemaleViral VaccinesSettore MED/26 - NeurologiaGeneral Medicine
researchProduct

WILLINGNESS TO RECEIVE COVID-l9 VACCINATION IN COSTUMERS ACCESSING COMMUNITY PHARMACIES IN THE PROVINCE OF PALERMO.ITALY.

2021

In Italy, vaccination against COVID-l 9 began on December 27, 2020. To date, 13,7 13,224 people in Italy are fully vaccinated, which accounts îor 25.3 oh of the general population, and 44.804 received at least one vaccination dose. Thc prescnt study aim to investigate willingness to receive COVID-I9 vaccination in costumers accessing a sample of community pharmacies in the Province of Palermo, Italy. A self- administered and anon),rnous questionnaire was carried out among costumers older than 18 ycars old between Dcccmbcr 2020 atrd March 2021. Three hundred and sixty-three subjects were enrolled in the study, 259 (71.3%) expressed their willingness to receive COVID-19 vaccination. The main …

COVID-19 vaccination willingness community pharmacies vaccine acceptance
researchProduct

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the …

2021

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health car…

Cancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)FAVO Federazione delle Associazioni di Volontariato in OncologiaReviewWHO World Health OrganizationCIPOMO Italian College of Primary Hospital Medical OncologistsSICO Società Italiana di Chirurgia OncologicaMedicalNeoplasmsHealth carePandemicMedicinecancerCentral Venous CathetersHumansFNOPI Federazione Nazionale Ordini Professioni InfermieristicheSocieties MedicalAIRO Associazione Italiana Radioterapia e Oncologia clinicaOncologistsClinical Trials as Topictreatmentbusiness.industryHigh mortalityAIOM Associazione Italiana di Oncologia medicaCancerNeoplasms therapyAIOM; cancer; COVID-19; treatment; vaccination; Central Venous Catheters; Clinical Trials as Topic; Humans; Influenza Vaccines; Oncologists; Practice Guidelines as Topic; COVID-19; COVID-19 Vaccines; Neoplasms; Societies MedicalCOVID-19medicine.diseasevaccinationCOMU College of University Medical OncologistsOncologyInfluenza VaccinesFamily medicineFOCE ConFederazione degli Oncologi Cardiologi e EmatologiPractice Guidelines as TopicESMO European Society for Medical OncologybusinessSocietiesSIPO Società Italiana di Psico-OncologiaAIOMESMO open
researchProduct

Comparison of vaccine strains and the virus causing the 1986 foot-and-mouth disease outbreak in Spain: epizootiological analysis

1990

RNAs of the most recent foot-and-mouth disease virus isolated in Spain (A5Sp86) during the 1986 outbreak, and of the three vaccine strains in use at that time in that country, have been compared. Although these viruses are serologically indistinguishable, differences have been found among them by T1 fingerprinting. This genetic heterogeneity affects the immunogenic VP1 gene, with amino acid changes located at the carboxyterminal end of the molecule. VP1-coding sequences obtained have been compared with those previously reported for European A5 FMDVs and it has been possible to trace their phylogenetic origin. The most parsimonious evolutionary tree obtained shows that the viruses analyzed a…

Cancer ResearchGenes ViralvirusesMolecular Sequence DataCattle DiseasesVirusDisease OutbreaksAphthovirusCapsidVirologymedicineAnimalsAmino Acid SequenceGenetic variabilityPhylogenyGeneticsAphthovirusBase SequencebiologyPhylogenetic treeFoot-and-mouth diseaseFoot-and-mouth disease virusGenetic heterogeneityOutbreakViral VaccinesRNA analysisbiology.organism_classificationmedicine.diseaseVirologyInfectious DiseasesSpainMolecular epizootiologyFoot-and-Mouth DiseaseRNA ViralGenetic variabilityCapsid ProteinsCattleFoot-and-mouth disease virusVirus Research
researchProduct

Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the…

2011

Abstract Strategies for antibody-mediated cancer immunotherapy, such as active immunization with virus-like particle (VLP)-based vaccines, are gaining increasing attention. We developed chimeric hepatitis B virus core antigen (HBcAg)-VLPs that display a surface epitope of the highly selective tumor-associated cell lineage marker claudin-18 isoform 2 (CLDN18.2) flanked by a mobility-increasing linker. Auto-antibodies elicited by immunization with these chimeric HBcAg-VLPs in 2 relevant species (mouse and rabbit) bind with high precision to native CLDN18.2 at physiologic densities on the surface of living cells but not to the corresponding epitope of the CLDN18.1 splice variant that differs b…

Cancer ResearchHepatitis B virusLung Neoplasmsmedicine.medical_treatmentMolecular Sequence DataCHO CellsAdenocarcinomaActive immunizationCancer VaccinesEpitopeMiceCricetulusAntigenVirus-like particleCancer immunotherapyAntibody SpecificityStomach NeoplasmsCell Line TumorCricetinaemedicineAnimalsHumansProtein IsoformsAmino Acid SequenceVaccines Virus-Like ParticleAutoantibodiesMice Inbred BALB Cbiologybusiness.industryAntibody-Dependent Cell CytotoxicityMembrane ProteinsVirologyMolecular biologyHepatitis B Core AntigensHBcAgHEK293 CellsOncologyCell cultureClaudinsbiology.proteinRabbitsAntibodybusinessCancer research
researchProduct

Abstract A110: Mutant MHC class II epitopes drive therapeutic immune responses to cancer

2016

Abstract Mutations are regarded as ideal targets for cancer immunotherapy. As neoepitopes with strict lack of expression in any healthy tissue, they are expected to be safe and could bypass the central tolerance mechanisms. Recent advances in nucleic acid sequencing technologies have revolutionized the field of genomics, allowing the readily targeting of mutated neoantigens for personalized cancer vaccination. We demonstrated in three independent murine tumor models that a considerable fraction of non-synonymous cancer mutations is immunogenic and that unexpectedly the immunogenic mutanome is pre-dominantly recognized by CD4+ T cells. RNA vaccination with such MHC class II restricted immuno…

Cancer ResearchMHC class IIbiologymedicine.medical_treatmentT cellImmunologyVirologyEpitopemedicine.anatomical_structureAntigenCancer immunotherapybiology.proteinmedicineCancer vaccineCentral toleranceCD8Cancer Immunology Research
researchProduct

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside

2014

Cancer is a disease caused by DNA mutations. Cancer therapies targeting defined functional mutations have shown clinical benefit. However, as 95% of the mutations in a tumour are unique to that single patient and only a small number of mutations are shared between patients, the addressed medical need is modest. A rapidly determined patient-specific tumour mutation pattern combined with a flexible mutation-targeting drug platform could generate a mutation-targeting individualised therapy, which would benefit each single patient. Next-generation sequencing enables the rapid identification of somatic mutations in individual tumours (the mutanome). Immunoinformatics enables predictions of mutat…

Cancer ResearchMutationbusiness.industryGenetic enhancementDrug Evaluation PreclinicalCancerGenomicsmedicine.diseasePrecision medicinemedicine.disease_causeBioinformaticsCancer VaccinesTranslational Research BiomedicalBreast cancerOncologyImmunologyMutationMedicineHumansPersonalized medicineCancer vaccineMinireviewRNA NeoplasmPrecision MedicinebusinessBritish Journal of Cancer
researchProduct